Table 1 Baseline characteristics of the studies included in meta-analysis
From: Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis
Study | Subjects | Location | Number (TLV/Control) | Age | LVEF (%) in TLV group/ control group (mean ± SD) | Control | Mean follow-up | TLV dose (mg)/duration (day) | Main outcomes |
|---|---|---|---|---|---|---|---|---|---|
Suzuki 2013 | AHF or acute exacerbation of chronic heart failure, NYHA II-IV | Japan | 54/55 | 74/75 | 47 ± 18/44 ± 14 | carperitide | 14 days | 3.75–15 mg/d | Symptoms, plasma BNP level, urine volume, adverse events |
Suzuki 2014 | AHF or acute exacerbation of chronic heart failure, NYHAII-IV | Japan | 54/55 | 74/75 | 47 ± 18/44 ± 14 | carperitide | 296 days | 3.75–15 mg/d | Serum sodium and potassium, plasma BNP levels, all-cause deaths |
Kimura 2015 | ADHF | Japan | 26/26 | 80.54/ 86.15 | 47.54 ± 16.75/ 56.73 ± 11.52 | furosemide | 7 days | 20 mg/d | WRF |
Matsue 2016 | AHF patients with renal dysfunction | Japan, America | 108/109 | 72.99/ 72.95 | 45.4 ± 18.1/ 46.8 ± 16.4 | no | 2 days | 15 mg/d | 48-h urine volume, WRF, net fluid loss, change in BNP, change in body weight, in-hospital death |
Matsue 2016 | AHF patients with renal dysfunction | Japan, America | 108/109 | 72.99/ 72.95 | 45.4 ± 18.1/ 46.8 ± 16.4 | no | 636 days | 15 mg/d | All-cause death |
Felker 2016 | AHF | America | 129/128 | 66/63 | 34 ± 17/32 ± 17 | placebo | 2 days | 30 mg/d | Symptomatic endpoints, decongestion and renal endpoints, clinical events |
Shanmugam 2016 | AHF and concomitant hyponatremia | India | 25/26 | 58.9/57 | 31.9 ± 12.2/ 29.2 ± 8.7 | placebo | 5 days | 15 mg/d | Sodium concentration, Likert score, adverse effects |
Jujo 2016 | AHF | Japan | 30/30 | 79/79 | NA | furosemide | 5 days | 7.5 mg/d | Urine volume, BNP, body weight, WHF |